Brains Bio creates the worlds’ first THC-based API
Added on 12 April 2024
In a press release which took place on the 6th of March, the cannabis pharmaceutics giant has proudly announced the successful synthetization of solid tetrahydrocannabinol as an Active Pharmaceutical Ingredient.
Brains Bio Chairman & CEO Ricky Brar stressed the revolutionary character of this process with complete confidence :
“Our solid D9 THC stands as a game-changer in the realm of cannabinoid-based drug development, offering our pharmaceutical partners an unparalleled tool to explore new frontiers in medicine. This breakthrough not only signifies a significant advancement in cannabinoid research but also underscores our commitment to driving innovation in pharmaceuticals. With this revolutionary technology, our partners are poised to unlock the full potential of cannabinoid-based treatments, paving the way for novel therapies that could transform patient care. Together, we’re dedicated to pushing the boundaries of what’s possible in cannabinoid medicine, with a shared vision of improving health outcomes and enhancing quality of life for patients worldwide”.
Brains Bios’ recent pharmaceutical discovery represents a pivotal leap forward in pharmaceutical innovation, offering a game-changing solution that promises to revolutionize drug development in the field of cannabinoid therapeutics, as the introduction of solid THC as an API signifies a seismic shift in how cannabinoids are harnessed for medical purposes. By providing a stable and precisely dosed form of THC, Brains Bio empowers researchers and pharmaceutical companies with a powerful tool to explore new frontiers in medicine. This innovation addresses longstanding challenges in cannabinoid research, such as dosage control and formulation stability, unlocking a new realm of possibilities for therapeutic interventions.
With solid THC, pharmaceutical researchers gain unprecedented precision and reliability in their studies, paving the way for enhanced treatment options across a spectrum of medical conditions, from chronic pain management to neurological disorders and mental health ailments. The potential impact of this innovation is vast, promising improved patient outcomes and transformative advancements in healthcare.
This groundbreaking development not only represents a significant advancement in cannabinoid-based medicine but also offers a higher value proposition that resonates with patients, healthcare providers, and investors alike. In 2022, the estimated worth of the global cannabis pharmaceuticals market was 1.03 billion EUR, with a compound annual growth rate of 62.5% from 2023 to 2030. With solid THC formulations gaining acceptance among healthcare professionals and patients, the adoption rate of cannabinoid-based medicines is likely to accelerate and this rapid adoption could potentially contribute to a higher CAGR as the sector experiences sustained growth in demand and market penetration.
In the ever-evolving landscape of medicinal cannabis, solid THC stands as a beacon of progress and possibility. With the potential to transcend borders, break down barriers, and reach patients in need, solid THC could not just expand markets—it could expand horizons, ushering in a new era of global healthcare innovation and accessibility.
Brains Bio's achievement underscores the company's unwavering commitment to pushing the boundaries of scientific discovery and driving innovation in pharmaceuticals. Positioned at the vanguard of cannabinoid medicine, Brains Bio sets a new standard for excellence in drug development, reaffirming its role as a leading force in shaping the future of healthcare. As the pharmaceutical industry embraces this game-changing innovation, the stage is set for a new era of cannabinoid-based therapies that hold the promise of a brighter, healthier future for patients worldwide.
Written by DANIEL CIUREA
More news
